Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
Immune checkpoint inhibition (ICI) therapies have reshaped the therapeutic landscape in lung cancer management, providing first-time improvements in patient response, prognosis, and overall survival. Despite their clinical effectiveness, variability in treatment responsiveness, as well as drug resis...
Main Authors: | Paraskevi Vryza, Timo Fischer, Elena Mistakidi, Apostolos Zaravinos |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-12-01
|
Series: | Translational Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523323001742 |
Similar Items
-
Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden
by: George Georgoulias, et al.
Published: (2022-10-01) -
The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
by: Camille Moeckel, et al.
Published: (2023-04-01) -
The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age
by: Yongfeng Wu, et al.
Published: (2020-04-01) -
Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma
by: Kai Ma, et al.
Published: (2022-11-01) -
The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients
by: Shengjin Cui, et al.
Published: (2023-02-01)